High placebo response during the first 2 weeks in both groups impacted primary outcome. Exploratory analysis of data from week 2 onwards shows nearly a 7 point greater reduction in MADRS scores in CBD group vs placebo group. Clearly, need further RCTs to test CBD efficacy.